Prospective Observational Study to Evaluate a Possible Change in APS Antibody Profiles After COVID-19 Infection or Vaccination
NCT05313048 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 82
Last updated 2022-12-21
Summary
Prospective observational study to evaluate a possible change in APS antibody profiles after COVID-19 infection or vaccination
Conditions
- Antiphospholipid Syndrome
- COVID-19 Infection
- COVID-19 Vaccination
Sponsors & Collaborators
-
Cardioangiologisches Centrum Bethanien
lead OTHER
Principal Investigators
-
Edelgard Lindhoff-Last, Prof. MD · Cardioangiology Center Bethanien
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-03-15
- Primary Completion
- 2022-10-24
- Completion
- 2022-10-24
Countries
- Germany
Study Locations
More Related Trials
-
Antiphospholipid Antibodies in Patients of Antiphospholipid Syndrome (APS) With Systemic Lupus Erythematosus (SLE).
NCT04963881 ·Status: COMPLETED
-
Highly Sensitive Serum Cardiac Troponin T and Cardiovascular Events in Patients With Systemic Lupus Erythematosus
NCT04580108 ·Status: COMPLETED
-
Follow-up Cohort of Patients With Antiphospholipid Syndrome
NCT07178925 ·Status: RECRUITING
-
Security Efficacy COVID-19 Vaccination
NCT05743361 ·Status: COMPLETED
-
Measurement of Anti-dsDNA by Both CLIFT & ELISA
NCT03303508 ·Status: UNKNOWN ·Phase: NA
-
Effect of Injectable Anticoagulants on Research for a Circulating Lupus-type Anticoagulant
NCT05416190 ·Status: COMPLETED ·Phase: NA
-
Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People
NCT04844489 ·Status: COMPLETED ·Phase: NA
-
Serum Prevalence of SARS-Cov-2 Antibodies in Pre-pandemic Blood Samples (SPARE)
NCT04712448 ·Status: ACTIVE_NOT_RECRUITING
-
Assessment of Rituximab Therapeutic Response Versus Conventional Treatment
NCT05553496 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Immunological Response to COVID-19 Vaccine in Patients With Autoimmune and Inflammatory Diseases Treated With Immunosuppressants and/or Biologics
NCT04870411 ·Status: TERMINATED
-
Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE
NCT05644210 ·Status: RECRUITING
-
Fetal-Hope Study: Home Monitoring of Fetal Heart Rate in SSA+ Pregnant Women
NCT05958446 ·Status: RECRUITING
-
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
NCT04976322 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)
NCT03189875 ·Status: COMPLETED
-
Post-COVID-19 Monitoring in Routine Health Insurance Data With Focus on Autoimmune Diseases (POINTED-AD)
NCT05606198 ·Status: COMPLETED
-
Anifrolumab Pregnancy Study
NCT07049653 ·Status: NOT_YET_RECRUITING
-
Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19
NCT05305651 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Leukocyte Populations in Patients With Chronic Inflammatory
NCT04749875 ·Status: NOT_YET_RECRUITING
-
Follow-up Study of Individuals with Autoantibodies Against Ro/SSA and La/SSB
NCT06594861 ·Status: RECRUITING
-
Circulating B-cell, Drug and Anti-drug Antibodies Monitoring in Patients Treated With Rituximab for Autoimmune Disorders
NCT07037732 ·Status: RECRUITING
-
Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases
NCT04530461 ·Status: UNKNOWN
-
Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)
NCT01475149 ·Status: COMPLETED
-
Ankylosing Spondylitis and Antiphospholipid Antibodies
NCT02809300 ·Status: UNKNOWN ·Phase: NA
-
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
NCT00198068 ·Status: RECRUITING
-
Prevalence and Seroconversion of COVID-19 in Autoimmune Diseases in Europe
NCT04397237 ·Status: UNKNOWN